Pelthos Therapeutics PTHS ZELSUVMI Royalty Agreement — Royalty agreement, percent of sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pelthos Therapeutics in its filing.
Tagged under the XBRL concept pths:RoyaltyAgreementVariableConsiderationPercentOfNetSales.
The source filing: Pelthos Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001919246-26-000070
Under the terms of the ZELSUVMI License, Ligand is entitled to (i) a 13% royalty on worldwide sales, excluding, Japan, of ZELSUVMI prior to the expiration of the initial royalty term, defined as on a country-by-country basis, the period of time commencing on the effective date and continuing until the expiration or termination of the last to expire valid claim of the patent rights that are included in the specified intellectual property and that cover the licensed product; (ii) a 10.4% royalty on worldwide sales, excluding, Japan, of ZELSUVMI after the expiration of the initial royalty term; (iii) upon the
Item 1. Financial Statements (unaudited)
FAQ
- What is Pelthos Therapeutics's ZELSUVMI royalty agreement — royalty agreement, percent of sales?
- Pelthos Therapeutics (PTHS) reported ZELSUVMI royalty agreement — royalty agreement, percent of sales of 13% in Q1 2026.
- What does ZELSUVMI royalty agreement — royalty agreement, percent of sales mean?
- This represents the contractual royalty rate applied to net sales of a licensed product or technology. It is a critical indicator of the cost structure and margin profile for products commercialized under third-party intellectual property agreements.
Ask your AI about Pelthos Therapeutics's zelsuvmi royalty agreement — royalty agreement, percent of sales.
Connect your AI assistant and compare it to peers, right in your chat.
